[Clinical efficacy and pharmacoeconomic characteristics of the neuroprotection with low doses of cortexin in the treatment of acute ischemic stroke].

Abstract

OBJECTIVE:

To assess the efficacy of the cytoprotective neuropeptide cortexin in the complex treatment in acute and early rehabilitation stages of ischemic stroke (II).

MATERIAL AND METHODS:

A multicenter prospective double-blind placebo-controlled trial has been carried out. Two hundreds and seventy-two patients with II have been enrolled in the trial. Cortexin was administered in low doses (10 mg three times a day intramuscular, using the following schemes: group 1: 2 courses of cortexin; group 2: 1 course of cortexin with the following course of placebo; group 3: two courses of placebo. The duration of treatment was 70 days. Patients were examined during 4 visits using clinical tests and instrumental methods.

RESULTS:

High efficacy and safety of cortexin in the complex treatment of patients with II has been shown. The best therapeutic effect was seen in group 1 (two 10-day courses of cortexin). The results were confirmed by the pharmacoeconomic analysis of treatment tactics based on the estimation of "net monetary benefit".

CONCLUSION:

Cortexin is recommended for treatment and rehabilitation of patients with II.

• Authors: V M Aliferova, M N Dadasheva, B M Doronin, A V Kovalenko, T M Lokshtanova, M Iu Martynov, K S Meshkova, K A Salimov, L V Stakhovskaia, Zh Iu Chefranova, N A Shamalov
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 114 Issue 4 Pg. 41-6 ( 2014) ISSN: 1997-7298 [Print] Russia (Federation)
• PMID: 24874316 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Intercellular Signaling Peptides and Proteins
• Neuroprotective Agents
• Peptides
• Placebos
• cortexin

Topics

• Adult
• Aged
• Aged, 80 and over
• Cytoprotection
• Double-Blind Method
• Drug Administration Schedule
• Economics, Pharmaceutical
• Female
• Humans
• Injections, Intramuscular
• Intercellular Signaling Peptides and Proteins
• Male
• Middle Aged
• Neuroprotective Agents (administration & dosage, economics)
• Peptides (administration & dosage, economics)
• Placebos
• Prospective Studies
• Stroke (drug therapy, pathology)
• Treatment Outcome